To meet increased demand for injectable products and help cut costs
Eisai has opened a new parenteral facility in Suzhou, China
Eisai has completed construction of a new production facility in Suzhou, Jiangsu, China to build up its local manufacturing capability to meet increasing demand in China for Methycobal, a peripheral neuropathy treatment.
The move is also expected to help cut costs by improving production efficiency in the medium-term.
The new facility has been built on an approximately 134,000m2 site in the Suzhou Industrial Park, which was recently bought by Eisai for the construction. It stands two floors above ground with a total floor space of approximately 3,300m2.
Serving as the company’s new base for parenteral manufacturing, the facility is initially equipped with a production line for Methycobal injection that has the capacity to manufacture approximately 60 million ampoules a year.
Eisai said it would expand the role of the new facility in the future to function as a global supply centre of injection products for a wider range of markets, including the rest of Asia and Latin America.